Sarah had a very busy schedule where she also managed to provide with excellent scientific lectures regarding rare tumors that hide the knowledge gaps of cancer immune escape. From her lectures, we could better grasp how difficult is to factor the most refractory cancer type to current immunotherapies, uveal melanoma. Despite the difficulties for developing proper in vivo models that would accelerate preclinical research in uveal melanoma, Sarah’s group advanced in establishing important scientific grounds, mostly given to the foundation of what is considered today one of the largest and successful biobanks for these rare intraocular tumors.
It has been a good month for Figueiredo’s group (MIORG) as one of the contributors of the InFLAMES flagship: a significant grant from the Jane and Aatos Erkko Foundation was just awarded. This funding opportunity will support our Academy of Finland project in the development of new adjuvant treatments to improve current immunotherapies for both cutaneous and ocular melanomas, where Sarah is an active collaborator.
Carlos De Figueiredo - InFlames